Cargando…

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in plasma exposure. The aim of this study was to evaluate the exposure–response relationship for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodier, Thomas, Puszkiel, Alicja, Cardoso, Evelina, Balakirouchenane, David, Narjoz, Céline, Arrondeau, Jennifer, Fallet, Vincent, Khoudour, Nihel, Guidi, Monia, Vidal, Michel, Declèves, Xavier, Csajka, Chantal, Alexandre, Jérôme, Cadranel, Jacques, Fabre, Elizabeth, Wislez, Marie, Goldwasser, François, Blanchet, Benoit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504753/ https://www.ncbi.nlm.nih.gov/pubmed/36145591 http://dx.doi.org/10.3390/pharmaceutics14091844

Ejemplares similares

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
por: Velev, Maud, et al.
Publicado: (2021)

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
por: Tiako Meyo, Manuela, et al.
Publicado: (2020)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022)

Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa
por: Millet, Aurélien, et al.
Publicado: (2021)

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Noé, Gaëlle, et al.
Publicado: (2019)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022)

Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab
por: Pasquiers, Blaise, et al.
Publicado: (2023)

From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure
por: Goutelle, Sylvain, et al.
Publicado: (2023)

Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma
por: Millet, Aurélien, et al.
Publicado: (2021)

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
por: Goutelle, Sylvain, et al.
Publicado: (2022)

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer
por: Courlet, Perrine, et al.
Publicado: (2022)

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
por: Buclin, Thierry, et al.
Publicado: (2020)

Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation
por: Terrier, Jean, et al.
Publicado: (2022)

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib
por: Noé, Gaёlle, et al.
Publicado: (2016)

Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial
por: Sottas, Oriane, et al.
Publicado: (2019)

Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children
por: Guidi, Monia, et al.
Publicado: (2019)

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2012)

Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study
por: Marin, Clémence, et al.
Publicado: (2021)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project
por: Monfort, Anaëlle, et al.
Publicado: (2023)

Phenotyping Indices of CYP450 and P-Glycoprotein in Human Volunteers and in Patients Treated with Painkillers or Psychotropic Drugs
por: Darnaud, Léa, et al.
Publicado: (2023)

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
por: Ginguay, Antonin, et al.
Publicado: (2022)

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
por: Bandiera, Carole, et al.
Publicado: (2023)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung
por: Saffroy, Raphaël, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2021)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study
por: Gaspar, Frédéric, et al.
Publicado: (2023)

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
por: Costantini, Adrien, et al.
Publicado: (2018)

Lung cancer is also a hereditary disease
por: Benusiglio, Patrick R., et al.
Publicado: (2021)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review
por: Fallet, Vincent, et al.
Publicado: (2021)

Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
por: Saade, Anastasia, et al.
Publicado: (2019)

Pericardial effusion under nivolumab: case-reports and review of the literature
por: Anastasia, Saade, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1b91aefsqj1db6ghgvoiuaqd98